These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35179742)

  • 21. Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction.
    Kurtul A; Yarlioglues M; Murat SN; Ergun G; Duran M; Kasapkara HA; Demircelik MB; Cetin M; Ocek AH
    Am J Cardiol; 2014 Aug; 114(3):342-7. PubMed ID: 24948493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating miR-660-5p is associated with no-reflow phenomenon in patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Zhang J; He L
    Anatol J Cardiol; 2021 May; 25(5):323-329. PubMed ID: 33960307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aggarwal P; Rekwal L; Sinha SK; Nath RK; Khanra D; Singh AP
    Ann Cardiol Angeiol (Paris); 2021 Jun; 70(3):136-142. PubMed ID: 33962782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Monocyte Count on Admission with the Angiographic Thrombus Burden in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Wang Z; Liu N; Ren L; Lei L; Ye H; Peng J
    Arq Bras Cardiol; 2018 Apr; 110(4):333-338. PubMed ID: 29538502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI.
    Acet H; Ertaş F; Akil MA; Bilik MZ; Aydin M; Polat N; Yildiz A
    Turk J Med Sci; 2016 Apr; 46(3):604-13. PubMed ID: 27513233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and validation of a prognostic model for predicting post-discharge mortality risk in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).
    Zhang L; Liu Z; Zhu Y; Wu M; Huang H; Yang W; Peng K; Zeng J
    J Cardiothorac Surg; 2024 Mar; 19(1):163. PubMed ID: 38555468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention.
    Zhang Q; Hu M; Ma S
    J Atheroscler Thromb; 2021 Dec; 28(12):1289-1297. PubMed ID: 33551392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of No-Reflow Phenomenon in Young Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Celik T; Balta S; Ozturk C; Kaya MG; Aparci M; Yildirim OA; Demir M; Unlu M; Demirkol S; Kilic S; Iyisoy A
    Angiology; 2016 Aug; 67(7):683-9. PubMed ID: 26369341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic immune-inflammation index predicts no-reflow phenomenon after primary percutaneous coronary intervention.
    Esenboğa K; Kurtul A; Yamantürk YY; Tan TS; Tutar DE
    Acta Cardiol; 2022 Feb; 77(1):59-65. PubMed ID: 33612077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CHA2DS2-VASc Score is a Predictor of No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Intervention.
    Ipek G; Onuk T; Karatas MB; Gungor B; Osken A; Keskin M; Oz A; Tanik O; Hayiroglu MI; Yaka HY; Ozturk R; Bolca O
    Angiology; 2016 Oct; 67(9):840-5. PubMed ID: 26685178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between epicardial adipose tissue and ST-segment resolution in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Zencirci E; Zencirci AE; Değirmencioğlu A; Karakuş G; Uğurlucan M; Özden K; Erdem A; Güllü AÜ; Ekmekçi A; Velibey Y; Erer HB; Çelik S; Akyol A
    Heart Vessels; 2015 Mar; 30(2):147-53. PubMed ID: 24413852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of no-reflow and major adverse cardiovascular events with a new scoring system in STEMI patients.
    Bayramoğlu A; Taşolar H; Kaya A; Tanboğa İH; Yaman M; Bektaş O; Günaydın ZY; Oduncu V
    J Interv Cardiol; 2018 Apr; 31(2):144-149. PubMed ID: 29193382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Machine learning prediction of no reflow in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Wang L; Bao P; Wang X; Xu B; Liu Z; Hu G
    Cardiovasc Diagn Ther; 2024 Aug; 14(4):547-562. PubMed ID: 39263488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The predictive value of the HALP score for no-reflow phenomenon and short-term mortality in patients with ST-elevation myocardial infarction.
    Toprak K; Toprak İH; Acar O; Ermiş MF
    Postgrad Med; 2024 Mar; 136(2):169-179. PubMed ID: 38356155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FGF-21: a novel biomarker predicting no-reflow in ST-segment elevation myocardial infarction.
    Koprulu D; Toprak K; Genc Tapar G; Ocak M
    Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3024-3029. PubMed ID: 38708459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Quisi A; Alıcı G
    J Clin Lab Anal; 2018 Nov; 32(9):e22598. PubMed ID: 29943408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of HAT
    Harbalıoğlu H; Genç Ö; Alıcı G; Quisi A; Yıldırım A
    Angiology; 2024 Jan; 75(1):44-53. PubMed ID: 37249481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel predictors and adverse long-term outcomes of No-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Refaat H; Tantawy A; Gamal AS; Radwan H
    Indian Heart J; 2021; 73(1):35-43. PubMed ID: 33714407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The non-HDL-C/HDL-C ratio is a strong and independent predictor of the no-reflow phenomenon in patients with ST-elevation myocardial infarction.
    Toprak K; Kaplangoray M; Akyol S; İnanır M; Memioğlu T; Taşcanov MB; Altıparmak İH; Biçer A; Demirbağ R
    Acta Cardiol; 2024 Apr; 79(2):194-205. PubMed ID: 38174719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between atherogenic index of plasma and no-reflow in patients with acute ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention.
    Süleymanoğlu M; Rencüzoğulları İ; Karabağ Y; Çağdaş M; Yesin M; Gümüşdağ A; Çap M; Gök M; Yıldız İ
    Int J Cardiovasc Imaging; 2020 May; 36(5):789-796. PubMed ID: 31919706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.